Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).
Open access · bronzeAbstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 232 papers, 10 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
232citing papers in PubMed, 10 pooled it
16.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
232 citing papers in PubMed, 10 syntheses or guidelines pooled it, 386 citations in OpenAlex.
- BRAF-targeted therapy in non-melanomatous BRAF-mutant tumours: a systematic review of broad but histology-modulated efficacy.International journal of clinical oncology · 2026Pooled it
- Prognostic factors and outcome measures after BRAF-directed targeted therapy of unresectable metastatic BRAFInvestigational new drugs · 2026Pooled it
- Tissue-Agnostic Targeting in Solid Tumors: A PRISMA-Compliant Meta-Analysis of Efficacy, Safety, and Resistance Determinants Across Histologies.Oncology research · 2026Pooled it
- Targeted therapy in advancedBMJ (Clinical research ed.) · 2025Pooled it
- Defining the Prognostic Significance of BRAF V600E in Early-Stage Colon Cancer: A Systematic Review and Meta-Analysis.Current oncology (Toronto, Ont.) · 2025Pooled it
- The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update.Cancer communications (London, England) · 2025Guideline
- A comprehensive overview of the molecular features and therapeutic targets in BRAFClinical and translational medicine · 2024Pooled it
- Analysis of Clinical Trials Using Anti-Tumor Traditional Chinese Medicine Monomers.Drug design, development and therapy · 2024Pooled it
- Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review.JAMA network open · 2022Pooled it
- Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy.Advances in cancer research · 2021Pooled it
- Blue LED photobiomodulation in the prevention of radiodermatitis in breast cancer survivors: a clinical trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Trial
- Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFCancer cell · 2025Trial
- First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial.Signal transduction and targeted therapy · 2025Trial
- Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial.Nature medicine · 2025Trial
- ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously UntreatedJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Trial
- A prospective phase II study of raltitrexed combined with S-1 as salvage treatment for patients with refractory metastatic colorectal cancer.Asia-Pacific journal of clinical oncology · 2021Trial
- Encorafenib Plus Cetuximab as a New Standard of Care for Previously TreatedJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Evaluation of the contribution of randomised cancer clinical trials evaluating agents without documented single-agent activity.ESMO open · 2020Trial
- Trial
172 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
20 authors at 11 institutions in 1 country.
Scott KopetzUniversity of Texas MD Anderson Cancer Center, Houston, TX.
Katherine A GuthrieSWOG Statistical and Data Management Center, Seattle, WA.
Van K MorrisUniversity of Texas MD Anderson Cancer Center, Houston, TX.
Heinz-Josef LenzUniversity of Southern California, Los Angeles, CA.
Anthony M MaglioccoH. Lee Moffit Cancer Center, Tampa, FL.
Dipen MaruUniversity of Texas MD Anderson Cancer Center, Houston, TX.
Yibing YanGenentech, South San Francisco, CA.
Richard LanmanGuardant Health, Redwood City, CA.
Ganiraju ManyamUniversity of Texas MD Anderson Cancer Center, Houston, TX.
David S HongUniversity of Texas MD Anderson Cancer Center, Houston, TX.
Alexey SorokinUniversity of Texas MD Anderson Cancer Center, Houston, TX.
Chloe E AtreyaHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA.
Luis A DiazMemorial Sloan Kettering Cancer Center, The Sidney Kimmel Cancer Center at Johns Hopkins University, Baltimore, MD.
Carmen AllegraUniversity of Florida, Gainesville, FL.
Kanwal P RaghavUniversity of Texas MD Anderson Cancer Center, Houston, TX.
Stephen E WangKaiser Permanente, South Sacramento, CA.
Christopher H LieuUniversity of Colorado Denver, Aurora, CO.
Shannon L McDonoughSWOG Statistical and Data Management Center, Seattle, WA.
Philip A PhilipWayne State University/Karmanos Cancer Institute, Detroit, MI.
Howard S HochsterRutgers Cancer Institute of New Jersey, New Brunswick, NJ.
The University of Texas MD Anderson Cancer Center · USGuardant (United States) · USJohns Hopkins University · USKaiser Permanente South Sacramento Medical Center · USMoffitt Cancer Center · USRutgers Cancer Institute of New JerseyUCSF Helen Diller Family Comprehensive Cancer Center · USUniversity of Colorado Denver · USUniversity of Florida · USUniversity of Southern California · USWayne State University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MNRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8MMember Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3MProject-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$167.6MSWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1MSWOG Statistics & Data Management Center complex - extension supplement for GY06U10CA180819 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Catherine M. Tangen · 2014 to 2026
$115.2MKaiser Permanente NCI National Community Oncology Research Program, NCORPUG1CA189821 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI Jennifer Marie Suga · 2014 to 2026
$44.4MHeartland Cancer Research NCORPUG1CA189830 · NCI · DECATUR MEMORIAL HOSPITAL · PI Bryan A. Faller · 2014 to 2026
$40.9MSoutheast Clinical Oncology Research Consortium, Inc. (SCOR)UG1CA189858 · NCI · SOUTHEAST CLINICAL ONCOL RES CONSORTIUM · PI Judith O Hopkins, William J Irvin · 2014 to 2026
$38.8MThe Pacific Cancer Research Consortium (PCRC), an NCORP Community SiteUG1CA189953 · NCI · SWEDISH MEDICAL CENTER, FIRST HILL · PI Alison Katherine Conlin, Charles Drescher · 2014 to 2026
$27.4MGulf South Minority/Underserved Clinical Trials Network (Gulf South M/U CTN)UG1CA189854 · NCI · LSU HEALTH SCIENCES CENTER · PI AUGUSTO C. OCHOA · 2014 to 2026
$27.1MNCORP of the Carolinas (Greenville Health System NCORP)UG1CA189972 · NCI · PRISMA HEALTH - UPSTATE · PI Ki Young Chung · 2014 to 2026
$17.9MNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA187238NCI NIH HHS U10 CA180801NCI NIH HHS U10 CA180819NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180826NCI NIH HHS U10 CA180830NCI NIH HHS U10 CA180834NCI NIH HHS U10 CA180835NCI NIH HHS U10 CA180858NCI NIH HHS U10 CA180868NCI NIH HHS U10 CA180888NCI NIH HHS UG1 CA180830NCI NIH HHS UG1 CA189809NCI NIH HHS UG1 CA189812NCI NIH HHS UG1 CA189821NCI NIH HHS UG1 CA189822NCI NIH HHS UG1 CA189830NCI NIH HHS UG1 CA189854NCI NIH HHS UG1 CA189858NCI NIH HHS UG1 CA189873NCI NIH HHS UG1 CA189952NCI NIH HHS UG1 CA189953NCI NIH HHS UG1 CA189954NCI NIH HHS UG1 CA189972NCI NIH HHS UG1 CA233324
Abstract
purpose
methodsOne hundred six patients with
resultsProgression-free survival, the primary end point, was improved with the addition of vemurafenib (hazard ratio, 0.50,
conclusionSimultaneous inhibition of EGFR and BRAF combined with irinotecan is effective in
Indexed as
MutationAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCetuximabColorectal NeoplasmsFemaleFollow-Up StudiesHumansIrinotecanMaleMiddle AgedNeoplasm MetastasisPrognosisProto-Oncogene Proteins B-rafBRAF protein, humanCetuximabIrinotecanProto-Oncogene Proteins B-raf
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.